Filing Details

Accession Number:
0001140361-21-037655
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-12 16:16:21
Reporting Period:
2021-11-09
Accepted Time:
2021-11-12 16:16:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1865494 Io Biotech Inc. IOBT Pharmaceutical Preparations (2834) 870909276
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1891515 Vanessa Malier C/O Io Biotech, Inc.
Ole Maaloes Veh 3
Copenhagen G7 2200
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-09 796,059 $0.00 796,059 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-11-09 267,977 $0.00 267,977 No 4 C Indirect See footnote
Common Stock Acquisiton 2021-11-09 162,500 $14.00 958,559 No 4 P Indirect See footnote
Common Stock Acquisiton 2021-11-09 162,500 $14.00 430,477 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series C Preferred Stock Disposition 2021-11-09 63,350 $0.00 796,059 $0.00
Common Stock Series C Preferred Stock Disposition 2021-11-09 21,325 $0.00 267,977 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date.
  2. The securities are held by Kurma Biofund III FPCI. Kurma Partners is the management company of Kurma Biofund III FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by Kurma Biofund III FPCI and disclaims Section 16 beneficial ownership of such securities held by Kurma Biofund III FPCI, except to the extent of her pecuniary interest therein, if any.
  3. The securities are held by SKCI FPCI. Kurma Partners is the management company of SKCI FPCI. The reporting person is a member of the board of directors of Kurma Partners, and may be deemed to share voting and investment power with respect to the shares beneficially owned by SKCI FPCI and disclaims Section 16 beneficial ownership of such securities held by SKCI FPCI, except to the extent of her pecuniary interest therein, if any.